Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michael Lincoff

Showing results (351-360 of 353) with videos related to

Pageof 36
Sort By:
You have reached the last page of results.This site can display upto 353 results.
The New England Journal of Medicine|November 15, 2011
Thrombin-receptor antagonist vorapaxar in acute coronary syndromesPierluigi Tricoci, Zhen Huang, Claes Held, et al.
Circulation|February 28, 2018
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsKaren A Hicks, Kenneth W Mahaffey, Roxana Mehran, et al.
Journal of the American College of Cardiology|March 3, 2018
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsKaren A Hicks, Kenneth W Mahaffey, Roxana Mehran, et al.
Pageof 36

Showing results (351-360 of 353) with videos related to

Sort By:
Pageof 36
You have reached the last page of results.This site can display upto 353 results.
The New England Journal of Medicine|November 15, 2011
Thrombin-receptor antagonist vorapaxar in acute coronary syndromesPierluigi Tricoci, Zhen Huang, Claes Held, et al.
Circulation|February 28, 2018
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsKaren A Hicks, Kenneth W Mahaffey, Roxana Mehran, et al.
Journal of the American College of Cardiology|March 3, 2018
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsKaren A Hicks, Kenneth W Mahaffey, Roxana Mehran, et al.
Pageof 36